NYSE:ANVS
Annovis Bio, Inc.
A pre-revenue biotech firm advancing gene editing therapies for rare diseases through a strategic partnership with Editas Medicine.
Key Metrics
Investment Thesis
Bull Case
Investors may consider this stock as a high-risk, high-reward speculative play on breakthrough gene therapies for rare diseases with significant unmet medical needs. The strategic partnership model mitigates commercialization risk while the company preserves capital through equity issuances and maintains positive cash on hand.
Bear Case
The absence of revenue and persistent net losses of over $25M annually signal an unsustainable financial trajectory without successful clinical milestones or partnerships. Significant dilution risks exist given the reliance on common share issuances to fund operations, potentially eroding shareholder value before product approval.
About Annovis Bio, Inc.
Annovis Bio, Inc. (ANVS) is a clinical-stage biotechnology company focused on developing novel therapies for rare genetic diseases, primarily in the fields of immunology and oncology. The company currently operates without commercial revenue, relying on strategic partnerships and equity financing to fund its extensive research and development pipeline targeting orphan indications.
Analysis
Management Discussion
The company reported a net loss of $24.6M for the latest period, driven by operating expenses of $26.7M which included $20.0M in R&D and $6.7M in G&A costs. Despite the negative cash flow from operations of $-21.9M, the firm secured $26.7M from financing activities, resulting in a net cash increase to $10.6M.
Industry Overview
The rare disease biotechnology sector is characterized by high upfront R&D costs, long development timelines, and regulatory hurdles but offers exclusive market potential for orphan drugs. Companies in this space often rely on licensing deals or partnerships to offset the immense financial burden of bringing therapies to market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $25.5M | $45.0M | $26.7M |
| Operating Income | $-25.5M | $-45.0M | $-26.7M |
| R&D | $16.5M | $38.8M | $20.0M |
| G&A | $9.0M | $6.2M | $6.7M |
| Stock-Based Comp | $9.2M | $4.6M | $3.8M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $182.7K | $-11.2M | $0 |
| Interest Income | — | — | $331.8K |
| Pre-Tax Income | $-25.3M | $-56.2M | $-26.7M |
| Income Tax | $0 | $0 | $-2.1M |
| Continuing Ops | $-25.3M | $-56.2M | $-24.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-25.3M | $-56.2M | $-24.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-25.3M | $-56.2M | $-24.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $36.0M | $10.2M | — |
| Cash & Equivalents | $28.4M | $5.8M | $10.6M |
| Other Current Assets | $7.6M | $4.5M | — |
| Long-Term Assets | $0 | $0 | — |
| Total Assets | $36.0M | $10.2M | $13.9M |
| Current Liabilities | $7.7M | $4.3M | $3.9M |
| Accounts Payable | $4.0M | $1.3M | $2.3M |
| Other Current Liab | $3.7M | $3.0M | $1.6M |
| Long-Term Liabilities | $0 | $13.7M | $737.0K |
| Total Liabilities | $7.7M | $18.0M | $4.6M |
| Shareholders' Equity | $28.3M | $-7.8M | $9.3M |
| Paid-In Capital | $82.4M | $102.5M | $144.2M |
| Retained Earnings | $-54.1M | $-110.3M | $-134.8M |
| Total L&E | $36.0M | $10.2M | $13.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-25.3M | $-56.2M | $-24.6M |
| Non-Cash Adjustments | $-5.5M | $22.8M | $4.2M |
| Working Capital Changes | $13.5M | $-6.6M | $-1.5M |
| Cash from Operations | $-17.3M | $-40.0M | $-21.9M |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $4.6K | $17.3M | $26.7M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-17.3M | $-22.6M | $4.8M |
| Beginning Cash | $45.7M | $28.4M | $5.8M |
| Ending Cash | $28.4M | $5.8M | $10.6M |
Frequently Asked Questions
How does Annovis Bio, Inc. make money?
The company's financial structure indicates a single primary segment focused on Research and Development, characterized by significant operating expenses of $26.7M and substantial R&D spending of $20.0M directed toward clinical trials and platform development.
What are the main risks for ANVS?
Total lack of current revenue streams creating high dependency on external capital; High burn rate with net losses of $24.6M requiring continuous fundraising; Clinical trial failure risks inherent to early-stage biotechnology development; Limited market size associated with rare disease indications.
What is ANVS's competitive advantage?
Access to proprietary gene editing platforms for rare disease targets; Strategic collaboration with Editas Medicine providing manufacturing and commercialization support; Strong balance sheet liquidity with over $10.6M in cash reserves to sustain operations until potential milestones are reached.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.